Abbott Announces Consideration for Debt Tender Offers
ABBOTT PARK, Ill., Nov. 8, 2012
ABBOTT PARK, Ill., Nov. 8, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced
today the reference yield and the total consideration for the nine series of
notes subject to the previously announced tender offers (the "Tender Offers")
to purchase for cash (i) any and all of its outstanding 4.35% Notes due March
2014 (the "2014 Notes"), 2.70% Notes due May 2015 (the "2015 Notes"), 5.875%
Notes due May 2016 (the "2016 Notes") and 5.60% Notes due November 2017 (the
"2017 Notes" and, collectively with the 2014 Notes, the 2015 Notes and the
2016 Notes, the "Any and All Notes," and such offers, the "Any and All
Offers") and (ii) up to an aggregate principal amount equal to the applicable
Series Tender Cap (as defined in the table below) of its 5.125% Notes due
April 2019 (the "2019 Notes"), 4.125% Notes due May 2020 (the "2020 Notes"),
6.15% Notes due November 2037 (the "2037 Notes"), 6.00% Notes due April 2039
(the "2039 Notes") and 5.300% Notes due May 2040 (the "2040 Notes" and,
collectively with the 2019 Notes, the 2020 Notes, the 2037 Notes and the 2039
Notes, the "Partial Offer Notes," and such offers, the "Partial Offers"). The
Partial Offer Notes, collectively with the Any and All Notes, are referred to
as "Notes," and each is referred to as a "Series" of Notes.
The Tender Offers are being made pursuant to the Offer to Purchase, dated Oct.
26, 2012 (the "Offer to Purchase") and related Letter of Transmittal, dated
Oct. 26, 2012 (the "Letter of Transmittal") previously distributed to holders
of the Notes, which set forth a description of the terms of the Tender Offers.
The total consideration to be paid in each of the Tender Offers has been
determined in the manner described in the Offer to Purchase by reference to a
fixed spread over the yield to maturity (the "Reference Yield") of the
applicable U.S. Treasury Security specified in the table below and on the
cover page of the Offer to Purchase in the column entitled "Reference U.S.
Treasury Security." Holders who validly tender and do not validly withdraw Any
and All Notes on or prior to the Any and All Expiration Date (as defined
below) that are accepted for purchase will receive the applicable "Any and All
Offer Consideration" listed in the table below.
Holders who validly tender and do not validly withdraw Partial Offer Notes on
or prior to the Early Tender Date (as defined below) that are accepted for
purchase will receive the applicable "Partial Offer Total Consideration"
listed in the table below, which includes an early tender payment of $30 per
$1,000 principal amount of Partial Offer Notes accepted for purchase (the
"Early Tender Payment"). Holders who validly tender and do not validly
withdraw Partial Offer Notes after the Early Tender Date but at or prior to
the Partial Offer Expiration Date (as defined below) that are accepted for
purchase will receive the Partial Offer Total Consideration minus the Early
In addition, Holders will receive accrued and unpaid interest on their Notes
up to, but excluding, the applicable settlement date.
Reference Any and All
U.S. Fixed Offer
Title of CUSIP Principal Series Reference Spread Consideration/
Security Amount Tender Treasury Yield (Basis Partial Offer
Numbers Outstanding Cap Points) Total
Notes 002824AQ3 $500,000,000 N/A due 0.234% 10 $1,053.60
Notes 002824AX8 $750,000,000 N/A due 0.309% 10 $1,057.81
due 2015 5/15/15
Notes 002824AT7 $2,000,000,000 N/A due 0.430% 15 $1,183.48
due 2016 5/15/16
Notes 002819AB6 $1,500,000,000 N/A due 0.659% 25 $1,230.90
due 2017 11/30/17
5.125% 1.50% due
Notes 002824AU4 $2,000,000,000 $944,000,000 3/31/19 0.927% 35 $1,235.55
4.125% 3.50% due
Notes 002824AW0 $1,000,000,000 $472,000,000 5/15/20 1.122% 15 $1,204.76
6.15% 3.00% due
Notes 002819AC4 $1,000,000,000 $472,000,000 5/15/42 2.753% 49 $1,496.05
6.00% 3.00% due
Notes 002824AV2 $1,000,000,000 $472,000,000 5/15/42 2.753% 43 $1,500.42
5.30% 3.00% due
Notes 002824AY6 $1,250,000,000 $590,000,000 5/15/42 2.753% 45 $1,381.88
(1) Per $1,000 principal amount of Notes validly tendered at or prior to the
Any and All Expiration Date, in the case of the Any and All Offers, and the
Early Tender Date, in the case of the Partial Offers, and accepted for
The Any and All Offers are scheduled to expire at 5 p.m., New York City time,
today, unless extended by Abbott (such date and time, as the same may be
extended, the "Any and All Expiration Date"). The Partial Offers are scheduled
to expire at 11:59 p.m., New York City time, on Nov. 26, 2012, unless extended
by Abbott (such date and time, as the same may be extended, the "Partial Offer
Expiration Date"). Holders of Partial Offer Notes must validly tender and not
validly withdraw their Partial Offer Notes at or before 5 p.m., New York City
time, today, unless extended by us (such date and time, as the same may be
extended, the "Early Tender Date"), to be eligible to receive the Partial
Offer Total Consideration. Tenders of Notes may be validly withdrawn at any
time prior to 5 p.m., New York City time, today, unless extended by us, and
after such time, except as provided in the Offer to Purchase or required by
law, Notes may not be validly withdrawn.
No Tender Offer is conditioned upon any minimum principal amount of Notes
being tendered. However, Abbott's obligation to accept for purchase, and to
pay for, Notes validly tendered and not validly withdrawn pursuant to any
Tender Offer is subject to, and conditioned upon, the satisfaction of the
conditions set forth in the Offer to Purchase.
Subject to the terms and conditions of the Any and All Offers, Abbott expects
to accept for purchase and pay for, on Nov. 13, 2012, all Any and All Notes
validly tendered and not validly withdrawn prior to the Any and All Expiration
Subject to the terms and conditions of the Partial Offers, Abbott expects to
accept for purchase and pay for, on Nov. 9, 2012 (the "Early Settlement
Date"), a portion of the Partial Offer Notes of any Series that are validly
tendered and not validly withdrawn prior to the Early Tender Date and,
promptly after the Partial Offer Expiration Date, accept for purchase and pay
for a principal amount of Partial Offer Notes of each Series up to the Series
Tender Cap, less any Partial Offer Notes of such Series purchased on the Early
Settlement Date (if any), in each case subject to proration as described in
the Offer to Purchase.
Abbott intends to call for redemption all of the Any and All Notes that remain
outstanding following the consummation of the Any and All Offers in accordance
with the terms of the applicable Indenture. In connection therewith, Abbott
expects to issue a redemption notice in respect of any such Any and All Notes
on or about the Any and All Expiration Date. However, Abbott is not obligated
to undertake any such redemption, and there can be no assurance that Abbott
will redeem Any and All Notes of all or any Series that remain outstanding
after consummation of the Any and All Offers.
This press release is neither an offer to purchase nor a solicitation of an
offer to sell securities. No offer, solicitation, purchase or sale will be
made in any jurisdiction in which such an offer, solicitation, or sale would
be unlawful. The Tender Offers are being made solely pursuant to terms and
conditions set forth in the Offer to Purchase and the Letter of Transmittal.
Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacturing and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company employs
approximately 91,000 people and markets its products in more than 130
Additional Information and Where to Find It
The complete terms and conditions of the Tender Offers are set forth in the
Offer to Purchase and Letter of Transmittal that was sent to holders of the
Notes. Holders are encouraged to read those documents carefully before taking
action with respect to the Tender Offers.
The Lead Dealer Managers for the Tender Offers are Morgan Stanley & Co. LLC,
Barclays Capital Inc., BofA Merrill Lynch and J.P. Morgan Securities LLC.
Questions regarding the Tender Offers may be directed to Morgan Stanley & Co.
LLC at 1 (800) 624-1808 (toll free) or 1 (212) 761-1057 (direct), to Barclays
Capital Inc. at 1 (800) 438-3242 (toll free) or 1 (212) 528-7581 (collect), to
BofA Merrill Lynch at 1 (888) 292-0070 (toll free) or 1 (980) 683-3215
(collect) or to J.P. Morgan Securities LLC at 1 (866) 834-4666 (toll free) or
1 (212) 834-2494 (collect).
Georgeson Inc. has been retained as Information Agent for the Tender Offers.
Requests for documents may be directed to Georgeson Inc. by telephone at 1
(212) 440-9800 (for banks and brokers) or 1 (800) 509-0984 (toll free).
None of Abbott, the Dealer Managers or the Information Agent for the Tender
Offers makes any recommendation that holders should tender, or refrain from
tendering, all or any portion of the principal amount of their Notes pursuant
to the Tender Offer. Holders must make their own decision as to whether to
tender their Notes.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning
Statements made in this news release contain forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of the
Securities and Exchange Act of 1934, as amended, including, without
limitation, statements related to our future growth, trends in our industry,
our financial or operational results, our financial or operational performance
and the planned separation of Abbott's research-based pharmaceutical company
from its diversified medical products company and the expected financial
results of Abbott and AbbVie after the separation. Such forward-looking
statements are predictive in nature, and may be based on current expectations,
forecasts or assumptions involving risks and uncertainties that could cause
actual outcomes and results to differ materially from the forward-looking
statements themselves. Such forward-looking statements may, without
limitation, be preceded by, followed by, or include words such as "believes,"
"expects," "anticipates," "estimates," "intends," "plans," "seeks,"
"forecasts" or similar expressions, or may employ such future or conditional
verbs as "may," "will," "should" or "would" or may otherwise be indicated as
forward-looking statements by grammatical construction, phrasing or context.
For those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the U.S. Private Securities Litigation
Reform Act of 1995.
Forward-looking statements are not guarantees of future performance. Economic,
competitive, governmental, technological and other factors that may affect
Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual
Report on Securities and Exchange Commission Form 10-K for the year ended Dec.
Except as required by applicable law, Abbott disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Abbott may not update
these forward-looking statements, even if its situation changes in the future.
All forward-looking statements attributable to Abbott are expressly qualified
by these cautionary statements.
Contact: Media, Scott Stoffel, +1-847-936-9502
Press spacebar to pause and continue. Press esc to stop.